Ipamorelin + Tesamorelin Blend

Key points

• The blend pairs ipamorelin, a growth hormone secretagogue, with tesamorelin, a GHRH analogue.
• Tesamorelin is a licensed medicine in some countries for an HIV related condition, but not in the UK.
• Neither component is licensed in the UK, and combining them does not change that.
• Both are on the WADA Prohibited List.

Quick facts

What it is

Blend of ipamorelin and tesamorelin

Marketed for

Growth hormone support

UK status

Not a licensed medicine; sold for research use

In sport

Both components prohibited

How it works

Tesamorelin acts through the GHRH receptor and ipamorelin through the ghrelin receptor, so together they aim for a larger growth hormone pulse. See the tesamorelin and ipamorelin entries for detail.

What the evidence shows

There is no evidence for this blend as a specific product. The components have their own evidence individually, strongest for tesamorelin in its licensed condition, and there are no controlled trials of the combination.

What it does not settle

• There are no controlled trials of this blend.
• The exact contents and ratios of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, including effects on glucose tolerance from tesamorelin.
• Because there is no licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

This blend has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use.

Common questions